Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24711-24720 Newer>

The Motley Fool July 23, 2007 Brian Lawler	Medarex Cheering for Its Partner The biopharma's partner advances one of its compounds into later stage clinical testing. Investors, take note.
The Motley Fool July 23, 2007 Rich Smith	Foolish Forecast: Looking for Lockheed The defense contractor is set to report second-quarter earnings. Investors, here is what you can expect to see.
The Motley Fool July 23, 2007 Lawrence Rothman	Safeway Stays Fresh The grocery chain hasn't passed its expiration date. Investors, take note.
The Motley Fool July 23, 2007 Anders Bylund	Fool on Call: Intel and AMD When all's said and done, it looks like we'll have an AMD way stronger than the 11.4% market share it has today, although nowhere nearly big enough to kill or maim mighty Intel.
The Motley Fool July 23, 2007 Anders Bylund	Foolish Forecast: Cupertino Appletini Apple is set to report its third-quarter 2007 earnings. Investors, here is what you can expect to see.
The Motley Fool July 23, 2007 Rick Aristotle Munarriz	Buck Back Mountain at Netflix Netflix's getting ready to report its second-quarter results, and investors seem worried about one thing: How much money the company stands to lose with the price cuts it announced over the weekend.
The Motley Fool July 23, 2007 David Lee Smith	Can It Get Better Than Schlumberger? The oilfield services leader is a quarterly font of impressive results and information. Investors, take note.
The Motley Fool July 23, 2007 S.J. Caplan	Scouting the Latest IPOs An investor's roundup of new-issue hits, misses, and no-shows. Netezza... SemGroup Energy Partners... Limco-Piedmont... etc.
The Motley Fool July 23, 2007 David Lee Smith	Caterpillar Is Still a Butterfly Despite a soft second quarter, Caterpillar still appears on track for a record year. Investors, take note.
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
<Older 24711-24720 Newer> Return to current articles.